ARTICLE | Strategy
Beyond the land Down Under
January 8, 2007 8:00 AM UTC
With a big infusion of cash coming in via its prescient investment in Domantis Ltd., Peptech Ltd. aims to provide a new benchmark for the cluster of Australian players aiming to play in global biotech. The company plans to use the US$141 million windfall to accelerate its transition from a research company to a biologics story with clinical development capabilities and a multinational presence.
When CEO John Chiplin first arrived in October 2005 after a stint as chief executive of the Intermediary Technology Institute (ITI) of Life Sciences in Scotland, he said "Peptech reminded me of a start-up with cash and some baggage that we needed to get shot of."...